TY - JOUR
T1 - Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico
AU - Campollo, Octavio
AU - Roman, Sonia
AU - Panduro, Arturo
AU - Hernandez, Gabriel
AU - Diaz-Barriga, Lino
AU - Balanzario, Mario C.
AU - Cunningham, James K.
N1 - Funding Information:
This project was funded by PROINV Program 00-52693 of the Universidad de Guadalajara . James Cunningham's work on this study was supported by the Mexico-US Fulbright-García Robles Program and the Canada-US Fulbright Program , as part of the Fulbright Canada-Mexico Joint Award in North American Studies.
PY - 2012/6/1
Y1 - 2012/6/1
N2 - Background: Research on hepatitis C virus (HCV) prevalence among non-injecting drug treatment clients in the United States, Europe and Asia indicate substantial differences by place. To date, little or no research on HCV and non-injection drug use (NIDU) has been conducted in Mexico. Methods: We examined the prevalence of HCV, hepatitis B virus (HBV), and HIV among non-injecting drug users (NIDUs) in community-based drug treatment (N= 122) and NIDUs in a prison-based drug treatment program (N= 30), both located in west central Mexico. Results: Among the community clients, prevalence was 4.1% (95% confidence interval [CI]: 1.8-9.2) for HCV, 5.7% for HBV (95% CI: 2.8-11.4), and 1.6% for HIV (95% CI: 0.4-5.8). Among the in-prison clients, prevalence was 40.0% (95% CI: 24.6-57.7) for HCV, 20.0% for HBV (95% CI: 9.5-37.3), and 6.7% for HIV (95% CI: 1.9-21.3). None of the clients were aware of being infected. Conclusion: The HCV prevalence found for the NIDU community treatment clients ranks among the lower HCV estimates published for NIDUs in treatment to date. The prevalence found for the in-prison clients ranks among the higher, raising a concern of possible elevated HCV infection among NIDUs in the west central Mexico prison-one compounded by the finding that none of this study's clients knew they were HCV positive.
AB - Background: Research on hepatitis C virus (HCV) prevalence among non-injecting drug treatment clients in the United States, Europe and Asia indicate substantial differences by place. To date, little or no research on HCV and non-injection drug use (NIDU) has been conducted in Mexico. Methods: We examined the prevalence of HCV, hepatitis B virus (HBV), and HIV among non-injecting drug users (NIDUs) in community-based drug treatment (N= 122) and NIDUs in a prison-based drug treatment program (N= 30), both located in west central Mexico. Results: Among the community clients, prevalence was 4.1% (95% confidence interval [CI]: 1.8-9.2) for HCV, 5.7% for HBV (95% CI: 2.8-11.4), and 1.6% for HIV (95% CI: 0.4-5.8). Among the in-prison clients, prevalence was 40.0% (95% CI: 24.6-57.7) for HCV, 20.0% for HBV (95% CI: 9.5-37.3), and 6.7% for HIV (95% CI: 1.9-21.3). None of the clients were aware of being infected. Conclusion: The HCV prevalence found for the NIDU community treatment clients ranks among the lower HCV estimates published for NIDUs in treatment to date. The prevalence found for the in-prison clients ranks among the higher, raising a concern of possible elevated HCV infection among NIDUs in the west central Mexico prison-one compounded by the finding that none of this study's clients knew they were HCV positive.
KW - Hepatitis b virus
KW - Hepatitis c virus
KW - Mexico
KW - Non-injection drug use
KW - Prison
UR - http://www.scopus.com/inward/record.url?scp=84861222719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861222719&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2011.11.009
DO - 10.1016/j.drugalcdep.2011.11.009
M3 - Article
C2 - 22138538
AN - SCOPUS:84861222719
VL - 123
SP - 269
EP - 272
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
SN - 0376-8716
IS - 1-3
ER -